Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NovaCardia & Domain: New-Model Spec Pharma Investing

This article was originally published in Start Up

Executive Summary

Domain partner Eckard Weber has become a master of the one-two punch in venture investing. The process (now in its third iteration following Merck's $350 million acquisition of NovaCardia): find a drug no one cares about; create a low-infrastructure company around it; find a second drug; sell off the lead drug through an acquisition; develop the second drug a bit more with the same management; then sell that one too. The first deal at a minimum pays back the investors; the second deal juices the returns. It's a model many VCs want to follow.
Advertisement

Related Content

Where Are They Now? Checking In On Four Cardiovascular Start-Ups
Merck Taking Aggressive Approach To Cardiovascular Development
Private Biotech M&A Review: Has the Market Lost Steam?
Pfizer's Serenex Acquisition Adds Fuel to Heat Shock Fire
Biopharma: Reviewing 2007 to Forecast 2008
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007
Venture Capital Still Has Place In Biotech Financing
Europe's New Spec Pharma Models
Stepping Out, Not Up: Better Returns for VCs Through M&A?
Jumpstart to Products

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091457

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel